USPTO Examiner DEVI SARVAMANGALA - Art Unit 1645

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18809763STRAIN OF LACTOBACILLUS HELVETICUS CAPABLE OF REMOVING MULTIPLE HEAVY METALS AND APPLICATION THEREOF IN GOAT MILK POWDERAugust 2024March 2025Allow711YesNo
18768336DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALSJuly 2024February 2025Allow700YesNo
18655708FimH Mutant, Compositions Therewith And Use ThereofMay 2024June 2025Allow1301YesNo
18654243COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND A FUNGICIDEMay 2024April 2025Allow1211YesNo
18593739Enhanced Microbial Therapeutic AgentsMarch 2024February 2025Allow1112YesNo
18590885AGROBACTERIUM FOR REDUCING UPTAKE OF HEAVY METALS BY WHEAT AND USE THEREOFFebruary 2024May 2025Abandon1411NoNo
18442348METHODS OF IMPROVING DESIRABLE TRAITS IN FOWLFebruary 2024June 2025Abandon1601NoNo
18441408PREPARATION OF LIVE VACCINESFebruary 2024April 2025Abandon1410YesNo
18440278MUTANT POREFebruary 2024March 2025Allow1301YesNo
18412561Probiotic Formulations for the Treatment and Alleviation of Metabolic and Oxidative Stress, Inflammation and NeurodegenerationJanuary 2024May 2025Allow1611YesNo
18393572Lactococcus Bacteria and Uses ThereofDecember 2023January 2025Allow1301YesNo
18390652COMPOSITIONS AND METHODS FOR INHIBITING SEIZURESDecember 2023March 2025Allow1511YesNo
18518137SHEWANELLA DECOLORATIONIS PRODUCING TETRODOTOXIN AND APPLICATION THEREOFNovember 2023August 2024Allow921YesNo
18507264SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATIONNovember 2023February 2025Abandon1501NoNo
18493141Factor H Binding Protein Variants and Methods of Use ThereofOctober 2023December 2024Allow1411YesNo
18490805ANTIBACTERIAL TREATMENT METHOD FOR A PATIENT WITH A SKIN WOUNDOctober 2023August 2024Allow1011YesNo
18463747MICROORGANISMS AND METHODS FOR REDUCING BACTERIAL CONTAMINATIONSeptember 2023July 2024Allow1101YesNo
18463461COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETESSeptember 2023November 2024Allow1411YesNo
18341018FIMH MUTANTS, COMPOSITIONS THEREWITH AND USE THEREOFJune 2023January 2025Allow1811YesNo
18213127TRIPLE VACCINE PROTECTS AGAINST BACTERIAL AND FUNGAL PATHOGENS VIA TRAINED IMMUNITYJune 2023March 2024Allow911YesNo
18336614OINTMENT-BASED SKIN WOUND TREATMENT METHODJune 2023October 2023Allow401YesNo
18329701MENINGOCOCCUS VACCINESJune 2023April 2025Allow2311YesNo
18201595IMMUNOGENIC PEPTIDE AGAINST GROUP A STREPTOCOCCUSMay 2023May 2025Allow2411YesNo
18316594Factor H Binding Protein Variants and Methods of Use ThereofMay 2023June 2024Allow1301YesNo
18142216COMPOSITIONS AND METHODS FOR A MULTI-ADJUVANT ONLY APPROACH TO IMMUNOPROPHYLAXIS FOR PREVENTING INFECTIONSMay 2023August 2024Abandon1601NoNo
18303512Influenza vaccine, composition, and methods of useApril 2023June 2025Abandon2621NoNo
18122835PROBIOTICS AND PROBIOTIC COMPOSITIONS FOR REGULATING BODY WEIGHTMarch 2023July 2024Allow1611YesNo
18109970IMMUNOGENIC COMPOSITIONSFebruary 2023June 2024Abandon1601NoNo
18156214IMMUNOCHROMATOGRAPHIC KIT AND METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSISJanuary 2023March 2025Allow2511YesNo
18154177IMMUNOGENIC TREATMENT OF CANCERJanuary 2023September 2024Abandon2020YesNo
18069759COMPOUNDS AND METHODS FOR BIOFILM DISRUPTION AND PREVENTIONDecember 2022May 2025Abandon2921NoNo
18065497NOVEL LACTIC ACID BACTERIA AND USE THEREOFDecember 2022March 2024Allow1501YesNo
18055044ARTIFICIAL SECRETION PEPTIDES FOR HETEROLOGOUS PROTEIN PRODUCTIONNovember 2022December 2024Abandon2501NoNo
18052455CHOLIX-DERIVED CARRIERS FOR ORAL DELIVERY OF HETEROLOGOUS PAYLOADNovember 2022November 2024Abandon2511NoNo
18051983POSTBIOTIC EXTRACT AND PREPARATION PROCESS AND USE THEREOFNovember 2022January 2024Allow1401YesNo
18051968POSTBIOTIC EXTRACT AND PREPARATION PROCESS AND USE THEREOFNovember 2022January 2024Allow1401YesNo
18050091COMPOSITION FOR DIAGNOSIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE, USING CHANGE IN SHORT-CHAIN FATTY ACID PRODUCING GUT BACTERIAL COMMUNITYOctober 2022December 2023Allow1401YesNo
17938454METHODS OF PRODUCING BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOFOctober 2022November 2024Allow2511YesNo
17931356METHODS AND COMPOSITIONS RELATED TO THE NEXT GENERATION VACCINESeptember 2022February 2025Allow2921YesNo
17821354Protection from Stress, Anxiety, Neuroinflammation, and Cognitive DysfunctionAugust 2022December 2023Allow1601YesNo
17816145Chimeric proteins for inducing immunity towards infection with S. aureusJuly 2022September 2024Allow2501YesNo
17814966FimH mutant, compositions therewith and use thereofJuly 2022February 2024Allow1801YesNo
17814988IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSEJuly 2022October 2024Abandon2711NoNo
17813233USE OF LACTIC ACID BACTERIA TO TREAT OR PREVENT GESTATIONAL DIABETES MELLITUSJuly 2022April 2025Allow3321YesNo
17862295TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASEJuly 2022April 2023Allow911YesNo
17730909Novel PD-L1 Targeting DNA Vaccine for Cancer ImmunotherapyApril 2022November 2023Abandon1901NoNo
17721115VACCINE TO PROTECT A PIG AGAINST ACTINOBACILLUS PLEUROPNEUMONIAEApril 2022October 2023Abandon1821YesNo
17714361COMPOSITION FOR PREVENTING OR TREATING MENOPAUSE, CONTAINING LACTOBACILLUS INTESTINALISApril 2022February 2024Allow2220NoNo
17707132METHOD FOR TREATING A SKIN WOUND HAVING A KLEBSIELLA PNEUMONIAE INFECTIONMarch 2022May 2023Allow1400YesNo
17705913VACCINE AGAINST NECROTIC ENTERITIS IN POULTRYMarch 2022September 2024Abandon3011NoNo
17764153NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOFMarch 2022April 2024Allow2521YesNo
17762572Functional Microbiological CoatingMarch 2022June 2025Allow3812YesNo
17574399FOOD COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR INHIBITING SJOGREN'S SYNDROME EACH CONTAINING BIFIDOBACTERIUM PSEUDOCATENULATUM C-RAPO (KCTC13986BP) AND BIFIDOBACTERIUM BIFIDUM ATT (KCTC13474BP)January 2022April 2023Allow1500YesNo
17573249FIMH MUTANTS, COMPOSITIONS THEREWITH AND USE THEREOFJanuary 2022March 2023Allow1411YesNo
17562055BORRELIA IMMUNOASSAYS AND MATERIALS THEREFORDecember 2021August 2024Allow3221YesNo
17554424E. COLI FIMH MUTANTS AND USES THEREOFDecember 2021March 2024Allow2722YesNo
17643942NOVEL LACTOCOCCUS LACTIS SUBSPECIES LACTIS ISOLATE WFLU-12 AND USE THEREOFDecember 2021March 2024Allow2711YesNo
17547639IMMUNOMODULATORY LIPOPOLYSACCHARIDE COMPOSITIONSDecember 2021September 2023Allow2121YesNo
17544377NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)December 2021February 2024Allow2611YesNo
17543207HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDSDecember 2021May 2023Abandon1710NoNo
17533552SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATIONNovember 2021August 2023Allow2121YesNo
17531314IN-VITRO POTENCY ASSAY FOR PROTEIN-BASED MENINGOCOCCAL VACCINESNovember 2021October 2023Abandon2301NoNo
17529396Cathelicidin-expressing lactic acid bacteriaNovember 2021September 2022Allow1011YesNo
17527002NOVEL LACTOBACILLUS PLANTARUM STRAIN ATG-K2, ATG-K6 OR ATG-K8, AND COMPOSITION FOR PREVENTING OR TREATING VAGINITIS COMPRISING SAMENovember 2021September 2024Allow3431YesNo
17511544APPLICATION OF A BILE ACID COMPOSITE BACTERIAL AGENT IN THE PREPARATION OF FEED ADDITIVES FOR MUTTON SHEEPOctober 2021January 2023Allow1411NoNo
17486299COMPOSITIONS AND METHODS FOR INHIBITING SEIZURESSeptember 2021September 2023Allow2411YesNo
17478584MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOFSeptember 2021October 2024Allow3721YesNo
17474885METHOD FOR IMPROVING WALKING CAPACITY OF ELDERLY SUBJECTSSeptember 2021February 2025Allow4111NoNo
17445781TEETH CLEANING ANIMAL CHEWAugust 2021June 2024Abandon3311YesNo
17401492BIOENGINEERED LACTOBACILLUS PROBIOTICS AND THE USES THEREOFAugust 2021October 2024Abandon3841YesNo
17428487NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOFAugust 2021October 2023Abandon2601NoNo
17384889MUTANT POREJuly 2021November 2023Allow2711YesNo
17371762METHODS, COMPOSITIONS AND KITS FOR TREATING A SUBJECT USING A RECOMBINANT HETEROMULTIMERIC NEUTRALIZING BINDING PROTEINJuly 2021May 2024Allow3421YesNo
17359375COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER USING BACTERIAJune 2021April 2024Abandon3411NoNo
17356941COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND A FUNGICIDEJune 2021February 2024Allow3111YesNo
17356958COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND AN INSECTICIDEJune 2021January 2024Allow3121YesNo
17415020COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING INCONTINENCE, OVERACTIVE BLADDER, OR MENSTRUAL CRAMPINGJune 2021October 2024Abandon4021NoNo
17347413MICROORGANISMS AND METHODS FOR REDUCING BACTERIAL CONTAMINATIONJune 2021August 2023Allow2601YesNo
17345576DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALSJune 2021April 2024Allow3461YesNo
17340141LACTOBACILLUS ACIDOPHILUS SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASESJune 2021October 2024Abandon4121YesYes
17337367Mutant Bordetella Strains and Methods of UseJune 2021October 2023Abandon2811NoNo
17331776SPECIFIC BACTERIA FOR THEIR USE AS A MEDICAMENT, IN PARTICULAR FOR CONTROLLING EXCESS WEIGHT, OBESITY, CARDIOMETABOLIC DISEASES AND INFLAMMATORY BOWEL DISEASESMay 2021June 2024Allow3711YesNo
17320706USE OF TLR4 MODULATOR IN THE TREATMENT OF COCCIDIOSISMay 2021April 2023Abandon2311NoNo
17319006RATIONALLY-DESIGNED MUTATIONS TO THE THRA GENE FOR ENHANCED LYSINE PRODUCTION IN E. COLIMay 2021June 2023Allow2502YesNo
17314563SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATIONMay 2021February 2022Allow911NoNo
17306313METHODS OF IMPROVING DESIRABLE TRAITS IN FOWLMay 2021February 2024Abandon3411NoNo
17228146COMPOSITIONS AND METHODSApril 2021March 2024Abandon3511YesNo
17226761PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USEApril 2021September 2023Allow2911YesNo
17221646FACTOR H BINDING PROTEIN VARIANTS AND METHODS OF USE THEREOFApril 2021February 2023Allow2201YesNo
17221177VHH BASED BINDING ANTIBODIES FOR ANTHRAX AND BOTULINUM TOXINS AND METHODS OF MAKING AND USING THEREFORApril 2021April 2024Allow3621YesNo
17220573Method of Treating Autoimmune Inflammatory Crohn's DiseaseApril 2021December 2022Allow2000YesNo
17301319CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPYMarch 2021May 2024Abandon3850YesNo
17301331CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPYMarch 2021March 2024Allow3550YesNo
17203920HIGH THROUGHPUT AFFINITY SAMPLE PREPARATION FOR MYCOTOXIN ANALYSISMarch 2021July 2024Allow4021YesNo
17193348PIRIN POLYPEPTIDE AND IMMUNE MODULATIONMarch 2021July 2023Abandon2901NoNo
17187264IMMUNOCHROMATOGRAPHIC KIT AND METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSISFebruary 2021April 2023Abandon2621NoNo
17180183VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCERFebruary 2021February 2024Abandon3611YesNo
17261347METHODS FOR DUAL DETECTION AND DIFFERENTIATION OF INFECTION BY MYCOBACTERIUM TUBERCULOSIS COMPLEX AND NONTUBERCULOUS MYCOBACTERIAJanuary 2021May 2024Abandon4021YesNo
17151445Multivalent Streptococcus VaccinesJanuary 2021October 2023Abandon3261YesNo
17150025FimH mutant, compositions therewith and use thereofJanuary 2021April 2022Allow1511YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DEVI, SARVAMANGALA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
4
(57.1%)
Examiner Reversed
3
(42.9%)
Reversal Percentile
64.0%
Higher than average

What This Means

With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
89
Allowed After Appeal Filing
16
(18.0%)
Not Allowed After Appeal Filing
73
(82.0%)
Filing Benefit Percentile
19.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DEVI, SARVAMANGALA - Prosecution Strategy Guide

Executive Summary

Examiner DEVI, SARVAMANGALA works in Art Unit 1645 and has examined 1,152 patent applications in our dataset. With an allowance rate of 61.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner DEVI, SARVAMANGALA's allowance rate of 61.7% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DEVI, SARVAMANGALA receive 2.04 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DEVI, SARVAMANGALA is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +50.4% benefit to allowance rate for applications examined by DEVI, SARVAMANGALA. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.6% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.7% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 87.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 78.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.2% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.